ReviewPharmaceuticals (Basel, Switzerland)2025

A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer's Disease.

Sara R Steinfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.